- Home
- ZCMD vs WINT Comparison
ZCMD vs WINT Comparison
Compare ZCMD & WINT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZCMD
- WINT
- Stock Information
- Founded
- ZCMD 2012
- WINT 1992
- Country
- ZCMD China
- WINT United States
- Employees
- ZCMD N/A
- WINT N/A
- Industry
- ZCMD Other Consumer Services
- WINT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ZCMD Real Estate
- WINT Health Care
- Exchange
- ZCMD Nasdaq
- WINT Nasdaq
- Market Cap
- ZCMD 6.2M
- WINT 5.3M
- IPO Year
- ZCMD 2020
- WINT 1995
- Fundamental
- Price
- ZCMD $2.00
- WINT $0.38
- Analyst Decision
- ZCMD
- WINT Hold
- Analyst Count
- ZCMD 0
- WINT 1
- Target Price
- ZCMD N/A
- WINT $7.00
- AVG Volume (30 Days)
- ZCMD 26.2K
- WINT 1.2M
- Earning Date
- ZCMD 01-01-0001
- WINT 11-27-2024
- Dividend Yield
- ZCMD N/A
- WINT N/A
- EPS Growth
- ZCMD N/A
- WINT N/A
- EPS
- ZCMD N/A
- WINT N/A
- Revenue
- ZCMD $17,406,104.00
- WINT N/A
- Revenue This Year
- ZCMD N/A
- WINT N/A
- Revenue Next Year
- ZCMD N/A
- WINT N/A
- P/E Ratio
- ZCMD N/A
- WINT N/A
- Revenue Growth
- ZCMD 1.01
- WINT N/A
- 52 Week Low
- ZCMD $1.00
- WINT $0.33
- 52 Week High
- ZCMD $5.50
- WINT $14.75
- Technical
- Relative Strength Index (RSI)
- ZCMD 61.05
- WINT 30.45
- Support Level
- ZCMD $1.91
- WINT $0.33
- Resistance Level
- ZCMD $1.47
- WINT $0.42
- Average True Range (ATR)
- ZCMD 0.27
- WINT 0.05
- MACD
- ZCMD 0.07
- WINT 0.03
- Stochastic Oscillator
- ZCMD 61.24
- WINT 11.11
About ZCMD Zhongchao Inc.
ZHONGCHAO Inc is a Cayman Islands-based provider of healthcare information, education, and training services. It provides services to healthcare professionals and the public in China. It offers online and onsite health information services, healthcare education programs, and healthcare training products, consisting of clinical practice training, open classes of popular medical topics, interactive case studies, academic conferences and workshops, continuing education courses, and articles and short videos with educational healthcare content.
About WINT Windtree Therapeutics Inc.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.